PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-12450.00%
Both yoy net incomes decline, with VET at -41.91%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-19.59%
Negative yoy D&A while VET is 0.88%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-402.38%
Negative yoy deferred tax while VET stands at 101.06%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
66.08%
Well above VET's 93.29% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
66.08%
Growth of 66.08% while VET is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
-57.89%
Both negative yoy, with VET at -97.46%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
2.27%
Some CFO growth while VET is negative at -1.12%. John Neff would note a short-term liquidity lead over the competitor.
28.84%
Lower CapEx growth vs. VET's 84.97%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
-99.66%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-304.27%
Both yoy lines negative, with VET at -6.69%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-160.74%
We reduce yoy invests while VET stands at 43.12%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
100.00%
Debt repayment growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.